Projects per year
Personal profile
Biography
Prof. Paul Stupple is a seasoned medicinal chemist with more than 20 years of experience in the global pharmaceutical industry and academia.
He has an outstanding track record of advancing projects to clinical development through progression of effective design strategies, development of exceptional teams and an enthusiastic approach to building strong multidisciplinary relationships.
Prof. Stupple has a BA and DPhil in Chemistry from the University of Oxford in the UK and spent the first decade of his career at Pfizer, UK where, as medicinal chemistry design leader with management responsibility, he provided leadership to multidisciplinary teams which delivered 6 clinical candidates of which 2 have advanced to Phase I clinical trials and 3 to Phase II.
Following a subsequent move to Australia, initially to WEHI and for the past 7 years at Monash University, Prof. Stupple led the Medicinal Chemistry program at the Cancer Therapeutics CRC (CTx), an organisation that ultimately became Canthera Discovery. In this role he led a chemistry program that resulted in two of the largest preclinical licencing agreements ever made in Australia. These included two projects; the first of which was licensed to Merck, Sharp and Dohme (MSD) in 2016, and the second was licensed to Pfizer in 2018 from which its lead compound was nominated as a development candidate and is currently undergoing Phase I clinical trials.
Research interests
Small molecule drug discovery
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Organic Chemistry, DPhil, University of Oxford
1 Oct 1996 → 20 Dec 1999
Award Date: 31 Jan 2000
Chemistry, BA, University of Oxford
1 Oct 1992 → 31 Jul 1996
Award Date: 31 Aug 1996
External positions
Director, Medicinal Chemistry, Canthera Discovery Ltd
1 Jan 2021 → …
Director, Medicinal Chemistry, Canthera Discovery Ltd
24 Jan 2012 → 31 Dec 2020
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Discovery of New Antimalarials with a Novel Mechanism of Action and Irresistible Target
Giannangelo, C. (Primary Chief Investigator (PCI)), Dillon, A. (Chief Investigator (CI)), Shackleford, D. (Chief Investigator (CI)), Edstein, M. (Chief Investigator (CI)), Creek, D. (Associate Investigator (AI)), Charman, S. (Associate Investigator (AI)), Burrows, J. N. (Associate Investigator (AI)), Stupple, P. (Associate Investigator (AI)), Gilson, P. (Associate Investigator (AI)), Niles, J. (Associate Investigator (AI)), Delves, M. (Associate Investigator (AI)) & Wittlin, S. (Associate Investigator (AI))
1/01/25 → 31/12/27
Project: Research
-
MedChem Australia – catalysing value creation in drug discovery
Stupple, P. (Primary Chief Investigator (PCI)), Charman, S. (Chief Investigator (CI)), Lessene, G. (Chief Investigator (CI)), Kassiou, M. (Chief Investigator (CI)), Mitchell, J. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Therapeutic Innovation Australia Limited, Monash University, Walter and Eliza Hall Institute of Medical Research (WEHI), University of Sydney
30/06/23 → 6/12/28
Project: Research
-
Drug Target Identification Platform
Creek, D. (Primary Chief Investigator (PCI)), Avery, V. M. (Chief Investigator (CI)), Pitson, S. M. (Chief Investigator (CI)), George, A. J. (Chief Investigator (CI)), Olechnowicz, S. (Chief Investigator (CI)), Baell, J. (Chief Investigator (CI)), Schittenhelm, R. (Chief Investigator (CI)), Li, J. (Chief Investigator (CI)), Langmead, C. (Chief Investigator (CI)), Stupple, P. (Chief Investigator (CI)), Drinkwater, C. (Chief Investigator (CI)), Flynn, B. (Chief Investigator (CI)), Brouwer, K. (Chief Investigator (CI)), Arndt, G. (Chief Investigator (CI)) & Newman, S. (Chief Investigator (CI))
Department of Health and Aged Care (Australia)
30/06/23 → 6/12/28
Project: Research
-
Advancing Preclinical Development of Novel GPCR-targeted Therapeutics for Heart Failure
Ritchie, R. (Primary Chief Investigator (PCI)), Figtree, G. A. (Chief Investigator (CI)), Qin, C. H. (Chief Investigator (CI)), May, L. (Chief Investigator (CI)), Nicholls, S. (Chief Investigator (CI)), Taylor, A. (Chief Investigator (CI)), Yang, J. Y. H. (Chief Investigator (CI)), Shackleford, D. (Chief Investigator (CI)), Schiattarella, G. (Chief Investigator (CI)), Pinto, A. (Chief Investigator (CI)), Drummond, G. (Chief Investigator (CI)), Horowitz, J. D. (Chief Investigator (CI)), Bubb, K. (Chief Investigator (CI)), Ng, H. H. (Chief Investigator (CI)), Vecchio, L. (Associate Investigator (AI)), Nelson, A. (Associate Investigator (AI)), Kirkpatrick, C. (Associate Investigator (AI)), McDonald, C. (Associate Investigator (AI)), Febbraio, M. (Associate Investigator (AI)), Vinh, A. (Associate Investigator (AI)), Odiba, J. (Associate Investigator (AI)), Brown, H. (Associate Investigator (AI)) & Stupple, P. (Chief Investigator (CI))
1/02/23 → 31/01/26
Project: Research
-
Development of a New Class of Formyl Peptide Receptor 1 (FPR1) Biased Agonists for the Treatment of Myocardial Infarction
Ritchie, R. (Primary Chief Investigator (PCI)), Stupple, P. (Chief Investigator (CI)), Qin, C. H. (Chief Investigator (CI)), May, L. (Chief Investigator (CI)), Vecchio, L. (Chief Investigator (CI)), Figtree, G. A. (Chief Investigator (CI)), Shackleford, D. (Chief Investigator (CI)), Chong, J. J. H. (Chief Investigator (CI)), Charman, S. (Associate Investigator (AI)) & McDonald, C. (Associate Investigator (AI))
1/01/23 → 31/12/25
Project: Research
-
Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer
Sharma, S., Chung, C. Y., Uryu, S., Petrovic, J., Cao, J., Rickard, A., Nady, N., Greasley, S., Johnson, E., Brodsky, O., Khan, S., Wang, H., Wang, Z., Zhang, Y., Tsaparikos, K., Chen, L., Mazurek, A., Lapek, J., Kung, P. P. & Sutton, S. & 59 others, , 19 Oct 2023, In: Cell Chemical Biology. 30, 10, p. 1191-1210 40 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access27 Citations (Scopus) -
Erratum: Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma (Proceedings of the National Academy of Sciences of the United States of America (2019)116(17990-18000)Doi: 10.1073/pnas.1901323116)
Hammad, S. A., Cullinane, C., Martin, C., Bacolas, Z., Ward, T., Chen, H., Slater, A., Ardley, K., Kirby, L., Chan, K. T., Brajanovski, N., Smith, L. K., Rao, A. D., Lelliott, E. J., Kleinschmidt, M., Vergara, I. A., Papenfuss, A. T., Lau, P., Ghosh, P. & Haupt, S. & 12 others, , 28 Apr 2020, In: Proceedings of the National Academy of Sciences of the United States of America. 117, 17, p. 9644-9645 2 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
Open Access1 Citation (Scopus) -
HBO1 is required for the maintenance of leukaemia stem cells
MacPherson, L., Anokye, J., Yeung, M. M., Lam, E. Y. N., Chan, Y. C., Weng, C. F., Yeh, P., Knezevic, K., Butler, M. S., Hoegl, A., Chan, K. L., Burr, M. L., Gearing, L. J., Willson, T., Liu, J., Choi, J., Yang, Y., Bilardi, R. A., Falk, H. & Nguyen, N. & 28 others, , 9 Jan 2020, In: Nature. 577, p. 266–270 5 p.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile127 Citations (Scopus) -
Temporal Analysis of Brd4 Displacement in the Control of B Cell Survival, Proliferation, and Differentiation
Kong, I. Y., Rimes, J. S., Light, A., Todorovski, I., Jones, S., Morand, E., Knight, D. A., Bergman, Y. E., Hogg, S. J., Falk, H., Monahan, B. J., Stupple, P. A., Street, I. P., Heinzel, S., Bouillet, P., Johnstone, R. W., Hodgkin, P. D., Vervoort, S. J. & Hawkins, E. D., 20 Oct 2020, In: Cell Reports. 33, 3, 22 p., 108290.Research output: Contribution to journal › Article › Research › peer-review
Open Access7 Citations (Scopus) -
Fragment screening for a protein-protein interaction inhibitor to WDR5
Dennis, M. L., Morrow, B., Dolezal, O., Cuzzupe, A. N., Stupple, A., Newman, J., Bentley, J., Hattarki, M., Nuttall, S. D., Foitzik, R., Street, I. P., Stupple, P. A., Monahan, B. J. & Peat, T. S., 1 Nov 2019, In: Structural Dynamics. 6, 6, 20 p., 064701.Research output: Contribution to journal › Article › Research › peer-review
Open AccessFile7 Citations (Scopus)
Press/Media
-
New Monash biotech company receives funding to halt the progression of Polycystic Kidney Disease
Denny Cottle, Ian Smyth, Paul Stupple & Yichao Zhao
30/05/23
1 item of Media coverage
Press/Media: Blogs, Podcasts and Social Media › Social Media Article
Equipment
-
Australian Translational Medicinal Chemistry Facility (ATMCF)
Stupple, P. (Manager)
Faculty of Pharmacy and Pharmaceutical SciencesFacility/equipment: Facility